PDCD1 and neoplasm: However, using both PD-1–blocking and cytotoxic T lymphocyte–associated protein 4–blocking (CTLA-4–blocking) antibodies in combination with TH-302 and αVEGFR-2 failed to improve tumor responses (Figure 3D).